Life Sciences

COVID-19 has prompted calls for reshoring of medical goods, including strict “Buy American” prescriptions. While reshoring is important, “Buy American” fails to recognize the value of the global supply chain and avoids addressing the real problem, China.
Life Sciences
Check a box to narrow search for individual content items that cover numerous issues.
July 16, 2020
Join ITIF for a discussion with experts and leaders from leading biopharmaceutical startups to discuss current challenges and opportunities, and what the federal government should and should not do to maintain this unique American strength.
June 17, 2020
Stephen Ezell gave a presentation to the Technology Transfer Society of DC about the history of the Bayh-Dole Act and its contributions to America’s innovation system, particularly in the life-sciences sector.
June 15, 2020
COVID-19 has prompted calls for reshoring of medical goods, including strict “Buy American” prescriptions. While reshoring is important, “Buy American” fails to recognize the value of the global supply chain and avoids addressing the real problem, China.
May 27, 2020
In contrast to what critics might assert, now is not the time to undermine either the IP rights or reasonable pricing reimbursement approaches that have underpinned so much successful biomedical innovation, and which will be key to getting through this crisis.
May 15, 2020
The global community will only be able to overcome the coronavirus pandemic through intense collaboration, turbocharged innovation, and open trade, uninhibited by artificial barriers or restrictions—particularly when comes to medical supplies and research data.
April 23, 2020
ITIF and the Bayh-Dole 40 Coalition hosted a video webinar delving into the critical role that partnerships between industry, academia, and federal labs will play in combating COVID-19, how these partnerships work, what risks they entail, why patents and licenses are so important in overcoming the risks inherent in developing drugs and vaccines, and how the Bayh-Dole Act enables the process for the benefit of people in the United States and around the world.
April 18, 2020
With two-thirds of the world in lockdown and no clear way out of the novel coronavirus crisis, it’s increasingly obvious that biopharmaceutical innovation will play a pivotal role.
April 3, 2020
As the urgency of finding a treatment and vaccine for the coronavirus accelerates, dozens of American biomedical companies, startups and universities are rushing to develop COVID-19 therapeutics. There’s a good chance the Bayh-Dole Act will play a critical behind-the-scenes role in facilitating these efforts.
March 30, 2020
Dozens of American drug companies and universities are rushing to create COVID-19 therapeutics—and they are better positioned to succeed than their counterparts anywhere else in the world.
February 6, 2020
Stephen Ezell presented about intellectual property’s impact on global health and life-sciences innovation at a Georgetown University course on Globalization and Public Health.

Pages